For decades, much of Alzheimer’s disease research has focused on two hallmark proteins: amyloid beta and tau. While these remain central to understanding the disease, scientists are increasingly uncovering another major factor — chronic brain inflammation.
New research supported by the BrightFocus Foundation is exploring how inflammation may begin at the cellular level — and whether interrupting that process could one day slow the progression of Alzheimer’s disease.
Looking Beyond Amyloid and Tau
Researcher Dr. Joe Herdy is studying a class of genetic elements known as LINE-1, sometimes described as “jumping genes.” These segments of DNA can copy and insert themselves into new locations within a cell’s genetic code.
In healthy brains, this activity is tightly regulated. But researchers believe that as the brain ages, LINE-1 activity may increase in certain neurons. When this happens, the process can resemble a viral infection inside the cell, potentially triggering the brain’s immune response.
Instead of protecting the brain, this immune activation may contribute to chronic inflammation — a feature widely recognized in Alzheimer’s disease but not yet fully understood.
The Role of Inflammation in Alzheimer’s
Chronic inflammation in the brain is increasingly viewed as a key contributor to neurodegeneration. Dr. Herdy’s work suggests that aging neurons may enter a state called “cellular senescence,” meaning they stop functioning normally but do not die. These cells can become inflammatory and may signal immune responses that further damage brain tissue.
By identifying how LINE-1 activity may trigger this inflammatory process, researchers hope to uncover new therapeutic targets — approaches that go beyond addressing amyloid plaques alone.
What This Could Mean for the Future
While this research is still in early stages, it opens the possibility of future treatments aimed at:
- Reducing harmful inflammation in the brain
- Targeting overactive genetic elements like LINE-1
- Protecting healthy neurons from damage
Some medications that affect similar genetic pathways are already used in other conditions. However, more study is needed to understand whether such treatments can be safely and effectively adapted for Alzheimer’s disease — particularly because reaching the brain through the blood-brain barrier presents challenges.
For caregivers and families, this research represents something important: progress. Scientists are expanding the understanding of Alzheimer’s beyond traditional pathways and exploring new directions that may one day translate into improved care and outcomes.
For Families Living with Alzheimer’s Today
While scientific breakthroughs are still developing, families navigating Alzheimer’s need support now.
At Delaware Hospice, we understand how deeply dementia affects not only the individual but also the entire family system. Our team provides compassionate care, symptom management, and emotional guidance for those living with advanced illness, helping caregivers focus on comfort, dignity, and meaningful connection.
We remain encouraged by ongoing research and grateful for organizations like BrightFocus Foundation that continue to invest in innovative approaches to understanding this disease.
This article was inspired by an interview published by the BrightFocus Foundation featuring researcher Dr. Joe Herdy and his work on neuroinflammation and LINE-1 activity in Alzheimer’s disease.
